bioMérieux
Market Cap
€13.4b
Last Updated
2020/06/06 23:22 UTC
Data Sources
Company Financials +
Executive Summary
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has bioMérieux's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-12.5%
BIM
-11.5%
FR Medical Equipment
9.2%
FR Market
1 Year Return
51.5%
BIM
42.8%
FR Medical Equipment
-2.3%
FR Market
Return vs Industry: BIM exceeded the French Medical Equipment industry which returned 42.8% over the past year.
Return vs Market: BIM exceeded the French Market which returned -2.4% over the past year.
Shareholder returns
| BIM | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.5% | -11.5% | 9.2% |
| 30 Day | -4.6% | -3.5% | 14.1% |
| 90 Day | 38.2% | 35.8% | 5.8% |
| 1 Year | 51.5%51.5% | 42.8%42.8% | -0.6%-2.3% |
| 3 Year | 73.8%72.2% | 43.9%42.2% | 11.4%2.5% |
| 5 Year | 247.2%239.3% | 144.5%138.9% | 31.9%15.0% |
Price Volatility Vs. Market
How volatile is bioMérieux's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Shareholders Are Thrilled That The bioMérieux (EPA:BIM) Share Price Increased 296%3 weeks ago | Simply Wall St
A Rising Share Price Has Us Looking Closely At bioMérieux S.A.'s (EPA:BIM) P/E Ratio1 month ago | Simply Wall St
bioMérieux S.A. (EPA:BIM) Earns Among The Best Returns In Its IndustryValuation
Is bioMérieux undervalued compared to its fair value and its price relative to the market?
48.96x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIM (€112.9) is trading above our estimate of fair value (€69.6)
Significantly Below Fair Value: BIM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIM is poor value based on its PE Ratio (49x) compared to the Medical Equipment industry average (44.3x).
PE vs Market: BIM is poor value based on its PE Ratio (49x) compared to the French market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: BIM is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: BIM is overvalued based on its PB Ratio (6.1x) compared to the FR Medical Equipment industry average (2.7x).
Next Steps
Future Growth
How is bioMérieux forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
11.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIM's forecast earnings growth (11.5% per year) is above the savings rate (0.6%).
Earnings vs Market: BIM's earnings (11.5% per year) are forecast to grow slower than the French market (13.7% per year).
High Growth Earnings: BIM's earnings are forecast to grow, but not significantly.
Revenue vs Market: BIM's revenue (7.5% per year) is forecast to grow faster than the French market (4.1% per year).
High Growth Revenue: BIM's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (13.2%).
Next Steps
Past Performance
How has bioMérieux performed over the past 5 years?
18.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIM has high quality earnings.
Growing Profit Margin: BIM's current net profit margins (10.2%) are lower than last year (10.6%).
Past Earnings Growth Analysis
Earnings Trend: BIM's earnings have grown by 18.1% per year over the past 5 years.
Accelerating Growth: BIM's earnings growth over the past year (6.4%) is below its 5-year average (18.1% per year).
Earnings vs Industry: BIM earnings growth over the past year (6.4%) exceeded the Medical Equipment industry -2%.
Return on Equity
High ROE: BIM's Return on Equity (12%) is considered low.
Next Steps
Financial Health
How is bioMérieux's financial position?
Financial Position Analysis
Short Term Liabilities: BIM's short term assets (€1.4B) exceed its short term liabilities (€1.2B).
Long Term Liabilities: BIM's short term assets (€1.4B) exceed its long term liabilities (€357.2M).
Debt to Equity History and Analysis
Debt Level: BIM's debt to equity ratio (20.5%) is considered satisfactory.
Reducing Debt: BIM's debt to equity ratio has reduced from 26.4% to 20.5% over the past 5 years.
Debt Coverage: BIM's debt is well covered by operating cash flow (88.3%).
Interest Coverage: BIM's interest payments on its debt are well covered by EBIT (18.6x coverage).
Balance Sheet
Next Steps
Dividend
What is bioMérieux's current dividend yield, its reliability and sustainability?
0.17%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: BIM's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.64%).
High Dividend: BIM's dividend (0.17%) is low compared to the top 25% of dividend payers in the French market (4.77%).
Stability and Growth of Payments
Stable Dividend: BIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: BIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BIM is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIM's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Alexandre Mérieux (45yo)
2.5yrs
Tenure
€1,310,165
Compensation
Mr. Alexandre Mérieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Mérieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined ...
CEO Compensation Analysis
Compensation vs Market: Alexandre's total compensation ($USD1.48M) is below average for companies of similar size in the French market ($USD3.89M).
Compensation vs Earnings: Alexandre's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.5yrs | €1.31m | 0.000050% €6.7k | |
| Employee Director & Head of CSR | 2.08yrs | €13.12k | 0.0025% €332.6k | |
| Executive VP of Purchasing and Information Systems & CFO | 2.25yrs | no data | no data | |
| Executive VP of Clinical Operations & COO | no data | no data | no data | |
| Investor Relations | no data | no data | no data | |
| Executive Vice President of Legal | no data | no data | no data | |
| Executive VP of Human Resources & Communications | 1.42yrs | no data | no data | |
| Executive Vice President of R&D | 2.25yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 7.67yrs | no data | no data | |
| Executive Vice President of Global Quality | 2.25yrs | no data | no data |
2.3yrs
Average Tenure
46.5yo
Average Age
Experienced Management: BIM's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.5yrs | €1.31m | 0.000050% €6.7k | |
| Employee Director & Head of CSR | 2.08yrs | €13.12k | 0.0025% €332.6k | |
| Founding Chairman | 2.83yrs | no data | no data | |
| Non-Independent Director | 13.75yrs | €41.00k | 0.00013% €17.4k | |
| Non-Independent Director | 10yrs | €55.00k | 0.000030% €4.0k | |
| Independent Director | 8.08yrs | €55.00k | 0.00013% €17.4k | |
| Independent Director | 6.08yrs | €46.00k | 0.00013% €17.4k | |
| Independent Director | 8.08yrs | €36.00k | 0.000050% €6.7k | |
| Independent Director | 3.08yrs | €36.00k | 0.000030% €4.0k | |
| Independent Director | 2.83yrs | €30.00k | 0.00015% €20.0k |
4.6yrs
Average Tenure
61.5yo
Average Age
Experienced Board: BIM's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
bioMérieux S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: bioMérieux S.A.
- Ticker: BIM
- Exchange: ENXTPA
- Founded: 1963
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €13.356b
- Shares outstanding: 118.30m
- Website: https://www.biomerieux.com
Number of Employees
Location
- bioMérieux S.A.
- 376 Chemin De l’Orme
- Marcy l'Etoile
- Rhône-Alpes
- 69280
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMXM.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 2004 |
| BIM | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Jul 2004 |
| 0RUG | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jul 2004 |
| EYWN | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 2004 |
| BIMP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jul 2004 |
Biography
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 23:22 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.